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when primary PCI is not possible within recommended door to
balloon time. Our objective was to conclude the efﬁcacy and safety
of tenecteplase in patients with STEMI.
Method: Data of 500 patients with STEMI who received tenecte-
plase in the last 1 year were analyzed.
Result: 90% patients had successful thrombolysis (SUCC.TH).
Hypertensives, diabetics, smokers and dyslipidemic patients had
SUCC.TH rates comparable to the general patient data. SUCC.TH
rates were signiﬁcantly lower in the elderly patients (>70 years,
86%, p < 0.0001), patients with history of IHD (88%, p < 0.0004) and
in patients receiving tenecteplase >6 h after onset of chest pain
(80%, p < 0.0001). SUCC.THwas signiﬁcantly higher in patientswho
received early thrombolysis (<3 h after onset of chest pain, 89%,
p = 0.006). Overall mortality was 1.5%. It was signiﬁcantly higher in
the elderly (4.5%), patients with history of IHD (3%), females (3%),
with delayed thrombolysis (5%). Overall incidence of ICH 0.3%,
other bleeds 2%, stroke 0.1% and ventricular tachyarrhythmias
2.5%were noted. Age>70 years, diabetes, dyslipidemia and history
of IHD were associated with a higher incidence of heart failure, re
infarction or ventricular tachyarrhythmias. Incidence of ICH and
other bleeds were comparable amongst all patient subgroups.
Ventricular arrhythmias were signiﬁcantly higher in dyslipi-
demics, with history of IHD, Killip class III & IV.
Conclusion: The study conﬁrmed the safety and efﬁcacy of tenec-
teplase.
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Background: Diabetes has been an Achilles heel of patients with
limus eluting drug-eluting stents (DES). In SPIRIT sub studies PES
had equivalent or better results than EES in Insulin requiring
diabetics. Our objective was to analyze this factor in Tuxedo-India
study, the largest ever DES study in patients with diabetesmellitus
comparing PES with EES.
Method: TUXEDO is a prospective, randomized, multicentre clin-
ical trial in patients with DM comparing the safety and efﬁcacy
outcomes of a PES with EES in a non-inferiority trial design.
We randomly assigned 1830 patients with diabetes mellitus to
receive either PES (TAXUS ElementTM) or EES (XIENCE PrimeTM)
in a non-inferiority trial design. Of these patients, 747 (40%) were
insulin requiring diabetics; 365/914 (39.9%) in PES group and
382/916 (41.7%) in the EES group. In a subset analyses, we evaluated
the 1-year rates of target-vessel failure (TVF), myocardial infarc-
tion (MI), stent thrombosis (ST), target-lesion revascularization
(TLR), and target-vessel revascularization (TVR) with PES or EES
in insulin requiring diabetics.
Results: The baseline characteristics of PES and EES groups in
insulin requiring diabetics were comparable. In insulin requiring
patients, there was a statistically signiﬁcant higher 1-year rate of
TVF in the PES group as compared to the EES group (7.9% vs. 3.4%,
p = 0.006). In addition, the rate of MI (4.4% vs. 1.3%, p = 0.01), ST
(3.0% vs. 0.5%, p = 0.009), TLR (5.2% vs. 1.0%; p = 0.001) andTVR (5.2%
vs. 1.0%; p = 0.001) was signiﬁcantly higher in the PES group com-
pared to the EES group over 1-year follow-up period.
Conclusion: PES, as compared to EES had higher rates of TVF,
MI, ST, TVR, and TLR at 1-year follow-up. The superiority of
EES, as compared to PES was maintained in insulin requiring
diabetics.
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Background: Prior trials (such as the SPIRIT trials) have shown the
superiority of EES over PES in general cohort. However, subgroup
analyses from these trials have failed to consistently show a
superiority of EES over PES in the diabetic cohort, leading to the
general notion that a 'taxol' eluting stent (such as PES) works as
well as a limus eluting stent (such as EES) in subjects with DM. Our
objective was to conduct a sufﬁciently powered randomized trial
comparing the efﬁcacy and safety of PESwith EES in a population of
patients with DM on drug treatment.
Method: TUXEDO is a prospective, randomized, multicenter clin-
ical trial in patients with DM comparing the safety and efﬁcacy
outcomes of a PES with EES in a non-inferiority trial design.
We randomly assigned a total of 1830 patients with DM, at 46
centers in India to receive either PES (TAXUS ElementTM Boston
scientiﬁc) or EES (Xience PrimeTM Abbott Vascular) without a
routine angiographic follow up. The primary endpoint was target
vessel failure deﬁned as a composite of cardiac death, target vessel
myocardial infarction or ischemia driven target vessel revascular-
ization at 12 months follow up.
Results: The mean age of the patients included was 58.4 years,
males 75.3% with the mean duration of DM being 6.5 years. Insulin
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